Season 1 · Episode 14
Navigating the FDA's New Ruling on Semaglutide and Tirzepatide - April 2025
What's Up, Doc? | Healthcare and Wellness Podcast · Miramont Wellness Centers
April 18, 20253m 48s
Audio is streamed directly from the publisher (feeds.podcastle.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of "What's Up, Doc?", Dr. John Bender and his trusted colleague, Janessa Hanna, discuss the latest FDA ruling that impacts semaglutide and tirzepatide GLP-1 medications. They dive into what this means for patients nationwide, especially in light of the discontinued production of compounded medications during the national shortage. The team also explores emerging options for personalized, compounded preparations to address side effects and shares insights into the evolving pharmaceutical landscape. Stay informed with this crucial update from Miramont Wellness Centers.
🎧Listen to our Podcast 🎧
Spotify: https://open.spotify.com/show/3yDSFFDkuYhY4mYocsTPjO?si=7721b690782a4a0b
ApplePodcasts: https://podcasts.apple.com/us/podcast/whats-up-doc/id1746818880
Learn more about Miramont Wellness Centers.
https://miramont.us
Call Us: (970) 225-5000
#SemaglutideUpdates #WeightLossJourney #MiramontWellnessCenters #GLP1 #Ozempic #WeightLossPlateau #Ketosis #SemaglutideAlternative #WellnessPodcast #WhatsUpDoc #FDA #Nationaldrugshortage